Literature DB >> 3916662

Complement and cancer: activation of the alternative pathway as a theoretical base for immunotherapy.

P D Cooper.   

Abstract

Activation of the APC is pointed out as the common factor in all sufficiently studied cancer treatments employing nonspecific, active immunotherapy. This chapter outlines the molecular biology of both APC and classical pathway of complement, summarizes the alternative pathway's biologic activities especially in relation to the C3/C5 convertase C3b,Bb, and its implications in the mechanism of host defense against malignancies, particularly relating to the activated macrophage. The many involvements of the APC in the various agents used for nonspecific active immunotherapy are reviewed, and possible clinical implications outlined. It is concluded that activation of the APC can be proposed as the specific theoretical basis so far lacking for this treatment modality and that it is accordingly feasible to attempt to monitor clinical application of this principle by fine-tuning of APC activation in cases of human cancer.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3916662     DOI: 10.1007/978-1-4612-5068-5_4

Source DB:  PubMed          Journal:  Adv Immun Cancer Ther        ISSN: 0178-2134


  6 in total

1.  The polysaccharide inulin is characterized by an extensive series of periodic isoforms with varying biological actions.

Authors:  Peter D Cooper; Thomas G Barclay; Milena Ginic-Markovic; Nikolai Petrovsky
Journal:  Glycobiology       Date:  2013-07-12       Impact factor: 4.313

2.  The non-inflammatory role of C1q during Her2/neu-driven mammary carcinogenesis.

Authors:  Silvio Bandini; Marco Macagno; Albana Hysi; Stefania Lanzardo; Laura Conti; Amanda Bello; Federica Riccardo; Roberto Ruiu; Irene Fiore Merighi; Guido Forni; Manuela Iezzi; Elena Quaglino; Federica Cavallo
Journal:  Oncoimmunology       Date:  2016-11-08       Impact factor: 8.110

3.  Exploitation of the complement system by oncogenic Kaposi's sarcoma-associated herpesvirus for cell survival and persistent infection.

Authors:  Myung-Shin Lee; Tiffany Jones; Dae-Yong Song; Jae-Hyuk Jang; Jae U Jung; Shou-Jiang Gao
Journal:  PLoS Pathog       Date:  2014-09-25       Impact factor: 6.823

4.  Commandeering a biological pathway using aptamer-derived molecular adaptors.

Authors:  Prabhat K Mallik; Kimi Nishikawa; Albert J T Millis; Hua Shi
Journal:  Nucleic Acids Res       Date:  2010-01-06       Impact factor: 16.971

Review 5.  Advax™, a novel microcrystalline polysaccharide particle engineered from delta inulin, provides robust adjuvant potency together with tolerability and safety.

Authors:  Nikolai Petrovsky; Peter D Cooper
Journal:  Vaccine       Date:  2015-09-25       Impact factor: 3.641

6.  Complement-Mediated Selective Tumor Cell Lysis Enabled by Bi-Functional RNA Aptamers.

Authors:  Prabhat K Mallik; Kimi Nishikawa; Pramit Mallik; Hua Shi
Journal:  Genes (Basel)       Date:  2021-12-29       Impact factor: 4.096

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.